Treatment and survival of patients with EGFR -mutated non-small cell lung cancer and leptomeningeal metastasis: A retrospective cohort analysis

• Published in: Lung cancer (Amsterdam, Netherlands) Netherlands), 2015-09, Vol.89 (3), p.255-261
• Main Authors: Kuiper, Justine L, Hendriks, Lizza E, van der Wekken, Anthonie J, de Langen, Adrianus J, Bahce, Idris, Thunnissen, Erik, Heideman, Daniëlle A.M, Berk, Yvonne, Buijs, Ed J.M, Speel, Ernst-Jan M, Krouwels, Frans H, Smit, Hans J.M, Groen, Harry J.M, Dingemans, Anne-Marie C, Smit, Egbert F
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Antineoplastic Agents - therapeutic use; Carcinoma, Non-Small-Cell Lung - genetics; Carcinoma, Non-Small-Cell Lung - mortality; Carcinoma, Non-Small-Cell Lung - pathology; Carcinoma, Non-Small-Cell Lung - therapy; Cohort Studies; Combined Modality Therapy; EGFR; Female; Hematology, Oncology and Palliative Medicine; Humans; Leptomeningeal metastasis; Lung Neoplasms - genetics; Lung Neoplasms - mortality; Lung Neoplasms - pathology; Lung Neoplasms - therapy; Male; Meningeal Neoplasms - diagnosis; Meningeal Neoplasms - secondary; Meningeal Neoplasms - therapy; Middle Aged; Mutation; Neoplasm Staging; NSCLC; Protein Kinase Inhibitors - therapeutic use; Pulmonary/Respiratory; Receptor, Epidermal Growth Factor - genetics; Retrospective Studies; TKI; Treatment Outcome
• ISSN: 0169-5002; 1872-8332
• DOI: 10.1016/j.lungcan.2015.05.023

Highlights • This is the largest study reporting on leptomeningeal metastasis (LM) in EGFR -mutated NSCLC-patients. • Median survival of EGFR -mutated NSCLC-patients with LM was 3.1 months. • Survival after LM-diagnosis in EGFR -mutated NSCLC-patients with LM may not be superior compared to existing data on that in EGFR -wild type NSCLC patients. • Six- and 12-month survival rates were 43.8% and 18.8%, respectively.